Get More Information on microRNA Market - Request Sample Report
The MicroRNA Market Size was USD 1.3 Billion in 2023 and is expected to Reach USD 7.7 Billion by 2032 and grow at a CAGR of 21.1% over the forecast period of 2024-2032.
The market size in the global market for microRNA, or miRNA, is significant as the instances of diseases like cancer, cardiovascular conditions, and neurological disorders have been constantly growing. Such illnesses require advanced and agile types of diagnostics and treatment, and the functions of miRNAs can control gene expression and serve as non-invasive biomarkers; therefore, the introduction of diagnostics involving miRNAs, especially those related to cancer, has only hastened developments in precision medicine with additional applications comprising potential utility to address critical healthcare challenges.
There is significant innovation in the market whereby firms in this industry continue to develop new and innovative technologies, formulations of products as well as methods of delivery. The stability of circulating miRNAs in bodily fluids including serum and plasma particularly in exosomes has offered new avenues for their application in diagnosis and prognosis, as well as enhancing their market presence. Thermo Fisher Scientific and Pfizer have strengthened collaborations and partnerships among top leaders in advancing the rollout of complex miRNA-based testing in underserved regions, hence contributing to market growth in the global arena.
The growth in the market is propelled by mergers and acquisitions, wherein companies like Merck KGaA, QIAGEN, and Thermo Fisher are expanding their geographic reach and product portfolios. Such activities enable the market players to advance into new regions, exploit emerging opportunities, and meet diverse healthcare demands that position the miRNA market for continued expansion across the regions.
Drivers
Evidence derived from these increasing clinical trials in chronic diseases and even further rising research that is constantly developing the clinical and preclinical use of miRNAs enhances the evidence that may be derived from such molecules as modulators of drug resistance, pathogenic biomarkers, and even therapeutic agents in various health-related issues. Increasing interest in miRNAs in a clinical setting enlightens one on the role of miRNAs in enhancing diagnostics and treatment results of a wide spectrum of chronic diseases.
Rapid surges in clinical studies examining the potential of miRNAs in the treatment of diseases, such as cancer, cardiovascular diseases, and neurological disorders, are driving market expansion. The importance of miRNAs has been demonstrated as they can control disease development and have proven to be valuable non-invasive biomarkers to be a cornerstone in developing new therapies.
The ever-increasing number of clinical trials is making the drug development and development of medical interventions based on miRNA a promising offer. The trend has the potential to drive forward the market scope in miRNA and to be used as a source for the advancement of therapy and improvement in patients for managing chronic diseases.
Restraints
As promising as miRNA might seem for clinical applications; particularly in chronic diseases such as cancer, cardiovascular disorders, and renal conditions, there stands a challenge due to issues of its safety and toxicity being matters of concern. It led to the suspension of several clinical trials intended to determine new miRNA-based therapies. As can be seen, Mirna Therapeutics, Inc., a clinical-stage pharmaceutical company, recently announced the discontinuation of its Phase 1 trial on MRX34, an experimental treatment for several types of cancers. According to this, "several patients in this ongoing Phase 1 trial have experienced severe immune-related adverse events, and further enrollment and dosing are being held pending assessment of these observations.
By Product And Services
In 2023, the service segment led the market with the highest revenue share of 58.8%. The service segment can be further divided into services including isolation & purification, miRNA cDNA synthesis, profiling, localization & quantification, functional analysis, and others. Some of the additional services target prediction and validation also support the growth of the segment. For example, an article in Nature published in January 2023 reported identifying plant-specific miRNA targets that were accurately predicted by P-TarPmiR. According to the article, the removal of animal data from the model resulted in better accuracy for the prediction of plant miRNA targets. The article further stated that animal data may interfere with a particular prediction of plant data. In the case of soybean genome-based miRNA targets, all of them were predicted successfully by the P-TarPmiR approach.
Meanwhile, the product segment is expected to experience significant growth during the forecast period. For this reason, this growth happens foremost in the increased application of miRNA as biomarkers for disease diagnosis and the increasing number of firms engaged in consumables such as kits and reagents for the study of miRNA expression.
By Application
Revenue share by segment in 2023 was led by the cancer segment because of huge investments in cancer research in the context of miRNA signatures. It further supports revenue dominance through clinical trials of miRNA-based therapies and diagnostic tests that aim at the subtypes and stages of cancer differentiation. miRNA diagnostics offer an improved approach to the diagnosis of certain types of cancer but are also considered a possible breakthrough in identifying cancers of unidentified origin.
The infectious disease segment is expected to grow at the highest CAGR during the forecast period. miRNAs are increasingly recognized as reliable biomarkers for various human diseases due to their crucial role in regulating gene expression at the post-transcriptional level. These factors are key contributors to the segment's growth. The infectious disease segment also witnessed a humongous growth spurt during the COVID-19 pandemic based on the significantly increased demand for miRNA research in viral diagnostics.
By End-User
The biotechnology and pharmaceutical companies segment led the market in 2023, primarily because they play an important role in establishing partnerships and collaborations with research institutions. Access through such partnerships brings the companies closer to discovering the latest cutting-edge research and allows them to take large-scale projects forward, thereby accelerating and enhancing the development of miRNA technology. For example, in the middle of August 2022, the Singapore biotechnology company, MiRXES, unveiled new capabilities that include an i4.0 manufacturing facility and two more laboratories; additionally, it announced a research project for the development of a multitalented screening test to detect cancer in collaboration with whomsoever. All the above initiatives are lining up to enhance its research and production capabilities aimed at developing miRNA-based detection tests.
The academic and government research institutes segment is likely to experience high growth in the forecast period. miRNA techniques and related products are increasingly being applied to various research studies conducted by academic and research institutions. This growing number of studies will further propel this market growth. For instance, in October 2022, researchers at the Institute of Science in Varanasi's School of Biotechnology found a microRNA that selectively kills and destroys cervical cancer cells. Research work based on this observation may eventually help come up with non-invasive cervical cancer therapy using microRNA therapy.
North America held the largest market share in 2023, driven by the strong local presence of key industry players such as Thermo Fisher Scientific, NanoString Technologies, Inc., and Merck KGaA. The region's miRNA market growth is attributed to a surge in research and development investments by these companies to create innovative and advanced products.
In the U.S., which accounted for the largest share of the North American market, major players like Thermo Fisher Scientific, Merck KGaA, and QIAGEN have well-established distribution networks, ensuring the easy availability of miRNA products and services. These companies maintain a strong emphasis on research and development, providing cutting-edge technological support to their customers. For instance, in August 2021, researchers at the Texas Heart Institute made breakthroughs in understanding disease through miRNA profiling, highlighting the crucial role of miRNAs in gene regulation and disease pathogenesis.
The Asia Pacific region is anticipated to witness the fastest growth during the forecast period. Factors such as a large target population, rapid adoption of new technologies, a rising number of startups, and a developing healthcare infrastructure contribute to this expansion. In China, the largest revenue contributor in the Asia Pacific market in 2023, increasing focus on precision medicine and the high potential of miRNAs in its development is expected to drive growth. Additionally, organizations such as the National Science Foundation and the National Nature Science Foundation are providing significant support for omics research. These entities promote collaborations between traditional Chinese knowledge and modern scientific advancements, with ongoing studies exploring the role of miRNAs in conjunction with traditional Chinese medicines like herbs.
Get Customized Report as per Your Business Requirement - Request For Customized Report
QIAGEN
New England Biolabs
Quantabio
Horizon Discovery Group plc.
NanoString Technologies, Inc.
Merck KGaA
Takara Bio, Inc.
LGC Limited
BioGenex
GeneCopoeia, Inc.
New England Biolabs
Heim Biotek
SeqMatic LLC
Miltenyi Biotec
Sistemic Scotland Limited
Biodynamics Laboratory Inc.
OriGene Tec
Synlogic
In October 2023, Thermo Fisher Scientific announced plans to invest USD 3.1 billion to acquire Olink Holding AB, aiming to expand its life sciences portfolio and enhance its capabilities in drug discovery.
In November 2023, QIAGEN launched new QIAcuity digital PCR kits and upgraded software, designed to help biopharma and food safety clients optimize and broaden their applications.
Report Attributes | Details |
Market Size in 2023 | US$ 1.3 Billion |
Market Size by 2032 | US$ 7.7 Billion |
CAGR | CAGR of 21.1% From 2024 to 2032 |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Data | 2020-2022 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
Key Segments |
|
Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
Company Profiles | Thermo Fisher Scientific, Inc., QIAGEN, New England Biolabs, Quantabio, Horizon Discovery Group plc., NanoString Technologies, Inc., Merck KGaA, Takara Bio, Inc., LGC Limited, BioGenex, GeneCopoeia, Inc. and Other Players |
Key Drivers | • Rising Clinical Trials for Chronic Disease Treatment Propel miRNA Market Growth |
Market Restraints | • Safety and Toxicity Concerns May Hinder miRNA Market Growth |
Ans: The MicroRNA Market is estimated to develop at a 21.1% CAGR.
Ans: The MicroRNA Market was valued at USD 1.3 billion in 2023 and is predicted to grow to USD 7.7 billion by 2032.
Ans: By Products & Services, The profiling, Quantification, and Localization segment will lead the market.
Ans: The increased need for improved diagnostic outcomes fuels and real-time polymerase chain reactions are expected to dominate the microRNA industry.
Ans: In 2023, microRNA-related profiling, localisation, and quantification services held a 24.84% share of the microRNA market. This is due to a rise in functional studies to examine the role of various miRNAs in various illnesses, as well as the increased usage of modern technologies like as NGS for reliable detection and quantification of miRNAs.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. MicroRNA Market Segmentation, by Products & Services
7.1 Chapter Overview
7.2 Services
7.2.1 Services Market Trends Analysis (2020-2032)
7.2.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Type
7.2.3.1 Type Market Trends Analysis (2020-2032)
7.2.3.2 Type Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Specimen
7.2.4.1 Specimen Market Trends Analysis (2020-2032)
7.2.4.2 Specimen Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Products
7.3.1 Products Market Trends Analysis (2020-2032)
7.3.2 Products Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Instruments
7.3.3.1 Instruments Market Trends Analysis (2020-2032)
7.3.3.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Consumables
7.3.4.1 Consumables Market Trends Analysis (2020-2032)
7.3.4.2 Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
8. MicroRNA Market Segmentation, by Application
8.1 Chapter Overview
8.2 Cancer
8.2.1 Cancer Market Trends Analysis (2020-2032)
8.2.2 Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Infectious Diseases
8.3.1 Infectious Diseases Market Trends Analysis (2020-2032)
8.3.2 Infectious Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Immunological Disorder
8.4.1 Immunological Disorder Market Trends Analysis (2020-2032)
8.4.2 Immunological Disorder Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Cardiovascular Disease
8.5.1 Cardiovascular Disease Market Trends Analysis (2020-2032)
8.5.2 Cardiovascular Disease Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Neurological Disease
8.6.1 Neurological Disease Market Trends Analysis (2020-2032)
8.6.2 Neurological Disease Market Size Estimates and Forecasts to 2032 (USD Million)
8.7 Others
8.7.1 Others Market Trends Analysis (2020-2032)
8.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. MicroRNA Market Segmentation, by End User
9.1 Chapter Overview
9.2 Biotechnology & Pharmaceutical Companies
9.2.1 Biotechnology & Pharmaceutical Companies Market Trends Analysis (2020-2032)
9.2.2 Biotechnology & Pharmaceutical Companies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Academic & Government Research Institutes
9.3.1 Academic & Government Research Institutes Market Trends Analysis (2020-2032)
9.3.2 Academic & Government Research Institutes Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.2.4 North America MicroRNA Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.5 North America MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.2.6.2 USA MicroRNA Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.3 USA MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.2.7.2 Canada MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.2.7.3 Canada MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.2.8.2 Mexico MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.2.8.3 Mexico MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.4 Eastern Europe MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.5 Eastern Europe MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.6.2 Poland MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.6.3 Poland MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.7.2 Romania MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.7.3 Romania MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.8.2 Hungary MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.8.3 Hungary MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.9.2 Turkey MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.9.3 Turkey MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.4 Western Europe MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.5 Western Europe MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.6.2 Germany MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.6.3 Germany MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.7.2 France MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.7.3 France MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.8.2 UK MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.8.3 UK MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.9.2 Italy MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.9.3 Italy MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.10.2 Spain MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.10.3 Spain MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.11.2 Netherlands MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.11.3 Netherlands MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.12.2 Switzerland MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.12.3 Switzerland MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.13.2 Austria MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.13.3 Austria MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.4 Asia Pacific MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.5 Asia Pacific MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.6.2 China MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.6.3 China MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.7.2 India MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.7.3 India MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.8.2 Japan MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.8.3 Japan MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.9.2 South Korea MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.9.3 South Korea MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.10.2 Vietnam MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.10.3 Vietnam MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.11.2 Singapore MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.11.3 Singapore MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.12.2 Australia MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.12.3 Australia MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.4 Middle East MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.5 Middle East MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.6.2 UAE MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.6.3 UAE MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.7.2 Egypt MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.7.3 Egypt MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.9.2 Qatar MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.9.3 Qatar MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.2.4 Africa MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.5 Africa MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.2.6.2 South Africa MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.6.3 South Africa MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.2.7.2 Nigeria MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.7.3 Nigeria MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America MicroRNA Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.6.4 Latin America MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.5 Latin America MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.6.6.2 Brazil MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.6.3 Brazil MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.6.7.2 Argentina MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.7.3 Argentina MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.6.8.2 Colombia MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.8.3 Colombia MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America MicroRNA Market Estimates and Forecasts, by Products & Services (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America MicroRNA Market Estimates and Forecasts, by Application(2020-2032) (USD Million)
10.6.9.3 Rest of Latin America MicroRNA Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11. Company Profiles
11.1 Thermo Fisher Scientific, Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 QIAGEN
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 New England Biolabs
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Quantabio
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Horizon Discovery Group plc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 NanoString Technologies, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Merck KGaA
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Takara Bio, Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 LGC Limited
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 BioGenex
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusio
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Services
Type
Isolation & Purification
miRNA cDNA Synthesis
Profiling, Localization, & Quantification
Functional Analysis
Others
Specimen
Whole Blood
Serum
Plasma
FFPE
Fresh Frozen Tissue
Others
Consumables
Specimens
Whole Blood
Serum
Plasma
FFPE
Fresh Frozen Tissue
Others
Workflow
Isolation & Purification
miRNA cDNA Synthesis
Profiling, Localization, & Quantification
Functional Analysis
Cancer
Infectious Diseases
Immunological Disorder
Cardiovascular Disease
Neurological Disease
Others
Biotechnology & Pharmaceutical Companies
Academic & Government Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Antimicrobial Resistance Surveillance Market was valued at USD 5.90 Billion in 2023 and is projected to grow to USD 9.50 billion by 2032 with a CAGR of 5.47% over the forecast period 2024-2032.
The White Biotechnology Market Size was valued at USD 445.34 billion in 2023, and is expected to reach USD 975.65 billion by 2031 and grow at a CAGR of 10.3% over the forecast period 2024-2031.
The Antiepileptic Drugs Market size was estimated at USD 18.21 billion in 2023 and is expected to reach USD 26.30 billion by 2031 at a CAGR of 4.70% during the forecast period of 2024-2031.
The Consumer Genomics Market size was estimated at USD 2.18 billion in 2023 and is expected to reach USD 14.08 billion by 2032 at a CAGR of 23.04% during the forecast period of 2024-2032.
The Radiation Oncology Treatment Planning Software Market size was estimated at USD 2.18 billion in 2023 and is expected to reach USD 4.75 billion by 2032 at a CAGR of 9.04% during the forecast period of 2024-2032.
The Global Biosimilars Market Size was USD 29.51 Billion in 2023 and expected to reach USD 127.92 Billion By 2032 and grow at a CAGR of 17.7% by 2024-2032.
Hi! Click one of our member below to chat on Phone